Explanipedia

Investigation of anti-SARS CoV-2 multimeric bicyclic peptide inhibitors in a range of pre-clinical therapeutic settings Open

Maximilian A. J. Harman, Katherine U. Gaynor, Guido Papa, Simone Pellegrino, G.A. Bezerra , et al. · 2025

The spread of respiratory viruses, such as Influenza and SARS-CoV-2 has presented significant challenges over the last 30 years with few effective therapeutic options available to this day. Bi-cyclic peptides represent a unique, modular, m…

Assessment of Favipiravir and Remdesivir in Combination for SARS-CoV-2 Infection in Syrian Golden Hamsters Open

Megan Neary, Eduardo Gallardo‐Toledo, Joanne Sharp, Joanne Herriott, Edyta Kijak , et al. · 2024

Medicine

Favipiravir (FVP) and remdesivir (RDV) have demonstrable antiviral activity against SARS-CoV-2. Here, the efficacy of FVP, RDV, and FVP with RDV (FVP + RDV) in combination was assessed in Syrian golden hamsters challenged with SARS-CoV- 2 …

Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case Open

Lee Tatham, Anja Kipar, Joanne Sharp, Edyta Kijak, Joanne Herriott , et al. · 2024

Medicine Biology Engineering

With some exceptions, global policymakers have recommended against the use of existing monoclonal antibodies in COVID-19 due to loss of neutralization of newer variants. The purpose of this study was to investigate the impact of Ronapreve …

Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models Open

Henry Pertinez, Amit Kaushik, Paul Curley, Usman Arshad, Eman El‐Khateeb , et al. · 2024

Medicine Chemistry

A significant challenge in the development of long-acting injectable drug formulations, especially for anti-infective agents, is delivering an efficacious dose within a tolerable injection volume. Co-administration of the extracellular mat…

Lack of antiviral activity of probenecid <i>in vitro</i> and in Syrian golden hamsters Open

Helen Box, Joanne Sharp, Shaun H. Pennington, Edyta Kijak, Lee Tatham , et al. · 2023

Medicine Biology

Objectives Antiviral interventions are required to complement vaccination programmes and reduce the global burden of COVID-19. Prior to initiation of large-scale clinical trials, robust preclinical data to support candidate plausibility ar…

Chemoprophylactic Assessment of Combined Intranasal SARS-CoV-2 Polymerase and Exonuclease Inhibition in Syrian Golden Hamsters Open

Eduardo Gallardo‐Toledo, Megan Neary, Joanne Sharp, Joanne Herriott, Edyta Kijak , et al. · 2023

Medicine Biology

Pibrentasvir (PIB) has been demonstrated to block exonuclease activity of the SARS-CoV-2 polymerase, protecting favipiravir (FVP) and remdesivir (RDV) from post-incorporation excision and eliciting antiviral synergy in vitro. The present s…

Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters Open

Megan Neary, Joanne Sharp, Eduardo Gallardo‐Toledo, Joanne Herriott, Edyta Kijak , et al. · 2023

Medicine

The successful development of a chemoprophylaxis against SARS-CoV-2 could provide a tool for infection prevention that is implementable alongside vaccination programmes. Nafamostat is a serine protease inhibitor that inhibits SARS-CoV-2 en…

Multivalent bicyclic peptides are an effective antiviral modality that can potently inhibit SARS-CoV-2 Open

Katherine U. Gaynor, Marina Vaysburd, Maximilian A. J. Harman, Anna Albecka, Philip D. Jeffrey , et al. · 2023

Chemistry Biology Medicine

COVID-19 has stimulated the rapid development of new antibody and small molecule therapeutics to inhibit SARS-CoV-2 infection. Here we describe a third antiviral modality that combines the drug-like advantages of both. Bicycles are entropi…

FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2 Open

Teresa Brevini, Mailis Maes, Gwilym J. Webb, Binu V. John, Claudia Fuchs , et al. · 2022

Medicine Biology

Preventing SARS-CoV-2 infection by modulating viral host receptors, such as angiotensin-converting enzyme 2 (ACE2) 1 , could represent a new chemoprophylactic approach for COVID-19 that complements vaccination 2,3 . However, the mechanisms…

Lack of antiviral activity of probenecid in Vero E6 cells and Syrian golden hamsters: a need for better understanding of inter-lab differences in preclinical assays Open

Helen Box, Shaun H. Pennington, Edyta Kijak, Lee Tatham, Claire H Caygill , et al. · 2022

Medicine Chemistry

Antiviral interventions are urgently required to support vaccination programmes and reduce the global burden of COVID-19. Prior to initiation of large-scale clinical trials, robust preclinical data in support of candidate plausibility are …

Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case Open

Lee Tatham, Anja Kipar, Joanne Sharp, Edyta Kijak, Joanne Herriott , et al. · 2022

Medicine Physics

Background Ronapreve demonstrated clinical application in post-exposure prophylaxis, mild/moderate disease and in the treatment of seronegative patients with severe COVID19 prior to the emergence of the Omicron variant in late 2021. Numero…

Evaluation of intranasal nafamostat or camostat for SARS-CoV-2 chemoprophylaxis in Syrian golden hamsters Open

Megan Neary, Helen Box, Joanne Sharp, Lee Tatham, Paul Curley , et al. · 2021

Medicine

Successful development of a chemoprophylaxis against SARS-CoV-2 could provide a tool for infection prevention implementable alongside vaccination programmes. Camostat and nafamostat are serine protease inhibitors that inhibit SARS-CoV-2 vi…

Edyta Kijak YOU? Author Swipe